Citi expects Chinese firms’ overseas fundraising to run through 2027

Citi's call matters less as a forecast than as a signal that the offshore issuance pipeline is being framed as multi-year rather than a single AI-driven window. The notable claim is sector broadening: biotech and advanced manufacturing would widen the issuer base beyond the hardware names that have anchored recent activity, shifting the mix of what reaches overseas investors. Whether that broadening actually shows up in deal flow, rather than staying concentrated in AI-adjacent issuers, is the open question worth watching.